+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast 2025-2030- Product Image
Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast 2025-2030- Product Image
Sale

Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012570
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The schizophrenia therapeutics market is undergoing significant transformation amid evolving scientific advancements and increased emphasis on patient-centered care. As stakeholders prioritize innovative interventions and improved outcomes, market complexities and shifting regulatory environments are driving the need for strategic decision-making.

Market Snapshot: Schizophrenia Therapeutics Market

The Schizophrenia Therapeutics Market grew from USD 5.89 billion in 2024 to USD 6.21 billion in 2025. It is expected to continue growing at a CAGR of 5.49%, reaching USD 8.12 billion by 2030. Underpinned by increasing demand for diversified treatments and innovation in digital health, the market reflects a dynamic environment shaped by clinical advancements and strategic partnerships. Investment in emerging therapeutics and integrated care models is supporting broader adoption and reinforcing the need for approaches that address unmet clinical needs and optimize patient outcomes.

Scope & Segmentation

This research provides a comprehensive analysis of market segments, regional trends, and key competitors, supporting senior executives in identifying priority opportunities and risks:

  • Non-Pharmacological Therapies: Cognitive-Behavioral Therapy (CBT), Electroconvulsive Therapy (ECT), Family Therapy
  • Pharmacological Therapies: Injectable Medications, Oral Medications
  • Therapeutic Class: First-Generation Antipsychotics, Second-Generation Antipsychotics, Mood Stabilizers, Selective Serotonin Reuptake Inhibitors
  • Mechanism of Action: Dopamine Receptor Antagonists, Glutamate Modulators, Serotonin Dopamine Activity Modulators
  • Formulation Type: Inserts and Patches, Liquid Solutions, Solid Tablets
  • End Users: Homecare Settings, Hospitals, Mental Health Clinics, Research Institutes
  • Patient Settings: Inpatient Care, Outpatient Care
  • Patient Demographics: Adult, Geriatric, Pediatric
  • Key Regions: Americas (including US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (featuring major markets such as UK, Germany, France, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, and other prominent countries)
  • Companies Analyzed: Over 30 leading and emerging players, including AbbVie Inc., Johnson & Johnson, Novartis AG, Teva Pharmaceuticals, AstraZeneca, and more

Key Takeaways for Decision Makers

  • Diversified treatment approaches highlight the significance of combined pharmacological and non-pharmacological regimens in delivering measurable improvements in symptom control and functional recovery.
  • The integration of digital therapeutics and personalized medicine is enabling enhanced monitoring, adherence, and outcome prediction, benefiting clinical practice and payer value assessment.
  • Collaborations among academic, industry, and regulatory partners are streamlining clinical development cycles, supporting faster entry of innovative therapies that target cognitive and negative symptom domains.
  • Segmenting patient profiles by age, comorbidity, and care setting is increasingly crucial in tailoring interventions, improving adherence, and optimizing resource allocation across healthcare systems.
  • Shifts in regulatory frameworks are fostering broader adoption of adaptive trial designs and patient-reported outcome measures, further shaping market access and reimbursement strategies.

Tariff Impact: Strategic Considerations in 2025

New United States 2025 tariffs are set to influence schizophrenia therapeutic supply chains, potentially raising raw material and production costs for companies reliant on imports. As organizations reassess supplier networks and manufacturing footprints, supply chain resilience and contract provisions will play a central role in protecting patient access and maintaining cost-efficiency. Payers and managed care entities are anticipated to intensify their focus on value-driven contracting and pharmacoeconomic justification to address rising financial pressures in procurement.

Methodology & Data Sources

Analytical methods include a combination of secondary research—reviewing peer-reviewed literature, regulatory filings, and industry reports—and primary research via structured interviews with clinical experts, industry leaders, and patient advocacy groups. Quantitative insights are reinforced through triangulation and statistical validation to ensure actionable findings on market access, pricing, and clinical development trends.

Why This Report Matters

  • Enables evidence-based strategic planning by synthesizing regional competitive intelligence and market-wide segmentation insights tailored for senior leadership teams.
  • Supports resource allocation to pipelines, partnerships, and supply chain investments most likely to yield differentiated clinical and economic value.
  • Guides preparation for regulatory changes and tariff effects, equipping organizations to remain agile in a shifting healthcare landscape.

Conclusion

The schizophrenia therapeutics market is advancing through a convergence of scientific innovation, technology enablement, and stakeholder collaboration. Organizations able to integrate patient needs with agile operational strategies are well positioned to lead in this complex and evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of personalized pharmacogenomic approaches in schizophrenia treatment pipelines
5.2. Rapid adoption of digital therapeutics and AI-enabled monitoring platforms for relapse prevention
5.3. Growing emphasis on long-acting injectable formulations to improve patient adherence rates
5.4. Expansion of novel glutamate receptor modulators for treatment-resistant schizophrenia populations
5.5. Increasing investment in anti-inflammatory agents targeting neuroinflammation in schizophrenia
5.6. Integration of real-world evidence studies to support label expansions and reimbursement decisions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Schizophrenia Therapeutics Market, by Type
8.1. Introduction
8.2. Non-Pharmacological Therapies
8.2.1. Cognitive-Behavioral Therapy (CBT)
8.2.2. Electroconvulsive Therapy (ECT)
8.2.3. Family Therapy
8.3. Pharmacological Therapies
8.3.1. Injectable Medications
8.3.2. Oral Medications
9. Schizophrenia Therapeutics Market, by Therapeutic Class
9.1. Introduction
9.2. Antipsychotics
9.2.1. First-Generation Antipsychotics
9.2.2. Second-Generation Antipsychotics
9.3. Mood Stabilizers
9.4. Selective Serotonin Reuptake Inhibitors
10. Schizophrenia Therapeutics Market, by Mechanism of Action
10.1. Introduction
10.2. Dopamine Receptor Antagonists
10.3. Glutamate Modulators
10.4. Serotonin Dopamine Activity Modulators
11. Schizophrenia Therapeutics Market, by Formulation Type
11.1. Introduction
11.2. Inserts and Patches
11.3. Liquid Solutions
11.4. Solid Tablets
12. Schizophrenia Therapeutics Market, by End Users
12.1. Introduction
12.2. Homecare Settings
12.3. Hospitals
12.4. Mental Health Clinics
12.5. Research Institutes
13. Schizophrenia Therapeutics Market, by Patient Settings
13.1. Introduction
13.2. Inpatient Care
13.3. Outpatient Care
14. Schizophrenia Therapeutics Market, by Patient Demographics
14.1. Introduction
14.2. Adult Patients
14.3. Geriatric Patients
14.4. Pediatric Patients
15. Americas Schizophrenia Therapeutics Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Schizophrenia Therapeutics Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Schizophrenia Therapeutics Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. AbbVie Inc.
18.3.2. Acadia Pharmaceuticals Inc.
18.3.3. Alkermes Plc
18.3.4. Amneal Pharmaceuticals, LLC
18.3.5. Astellas Pharma Inc.
18.3.6. AstraZeneca plc
18.3.7. BioXcel Therapeutics, Inc.
18.3.8. Boehringer Ingelheim International GmbH
18.3.9. Bristol Myers Squibb Company
18.3.10. Cipla Limited
18.3.11. Delpor, Inc.
18.3.12. Dr. Reddy’s Laboratories Ltd.
18.3.13. Eli Lilly and Company
18.3.14. Gedeon Richter Plc
18.3.15. GlaxoSmithKline plc.
18.3.16. Glenmark Pharmaceuticals Limited
18.3.17. Johnson & Johnson Services, Inc.
18.3.18. Lundbeck A/S
18.3.19. Lupin Limited
18.3.20. Luye Pharma Group Ltd
18.3.21. Lyndra Therapeutics Inc
18.3.22. Meiji Holdings Co., Ltd.
18.3.23. Merck & Co., Inc.
18.3.24. Neurocrine Biosciences, Inc.
18.3.25. Novartis AG
18.3.26. Otsuka Holdings Co., Ltd.
18.3.27. Pfizer Inc.
18.3.28. Reviva Pharmaceuticals Holdings, Inc.
18.3.29. Sanofi S.A
18.3.30. Sumitomo Pharma Co., Ltd.
18.3.31. Sun Pharmaceutical Industries Limited
18.3.32. Takeda Pharmaceutical Company Limited
18.3.33. Teva Pharmaceutical Industries Ltd.
18.3.34. Torrent Pharmaceuticals Ltd.
18.3.35. Vanda Pharmaceuticals Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. SCHIZOPHRENIA THERAPEUTICS MARKET: RESEARCHAI
FIGURE 30. SCHIZOPHRENIA THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 31. SCHIZOPHRENIA THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 32. SCHIZOPHRENIA THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 129. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 130. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 131. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 132. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 133. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 134. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 135. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 136. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 137. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 138. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 139. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 142. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 143. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 144. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 145. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 146. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 147. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 150. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 151. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 152. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 153. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 154. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 155. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 158. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 159. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 160. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 161. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 249. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 250. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 251. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 252. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 253. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 254. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 255. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 256. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 257. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 258. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 259. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 262. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 263. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 264. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 265. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 268. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 269. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 270. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 271. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 272. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 273. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 274. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 275. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 276. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 277. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 278. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 279. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 280. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 281. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 282. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 283. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 284. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 285. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2024 (USD MILLION)
TABLE 286. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 288. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA SCHIZOPHRENIA THERAPEUTICS MAR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Schizophrenia Therapeutics market report include:
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi S.A
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.21 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.12 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

Schizophrenia Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Schizophrenia Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Schizophrenia Therapeutics - Global Strategic Business Report - Product Image

Schizophrenia Therapeutics - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Antipsychotic Drugs - Global Strategic Business Report - Product Image

Antipsychotic Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Schizophrenia Drugs Market Size, Share & Trends Analysis Report by Drug Class (Second- Generation Antipsychotics, Third-Generation Antipsychotics), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Schizophrenia Drugs Market Size, Share & Trends Analysis Report by Drug Class (Second- Generation Antipsychotics, Third-Generation Antipsychotics), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Schizophrenia Market Report and Forecast 2025-2034 - Product Image

Schizophrenia Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.